Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …
circulation; however, it is currently unknown whether it elicits effective immune responses in …
A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine
ABSTRACT The US Food and Drug Administration-authorized mRNA-and adenovirus-
based SARS-CoV-2 vaccines are intramuscularly injected in two doses and effective in …
based SARS-CoV-2 vaccines are intramuscularly injected in two doses and effective in …
Considerations for novel COVID-19 mucosal vaccine development
W Alturaiki - Vaccines, 2022 - mdpi.com
Mucosal surfaces are the first contact sites of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Most SARS-CoV-2 vaccines induce specific IgG responses …
coronavirus 2 (SARS-CoV-2). Most SARS-CoV-2 vaccines induce specific IgG responses …
[HTML][HTML] Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses
DM Morens, JK Taubenberger, AS Fauci - Cell host & microbe, 2023 - cell.com
Viruses that replicate in the human respiratory mucosa without infecting systemically,
including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other" …
including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other" …
An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection
PA van der Ley, A Zariri, E van Riet… - Frontiers in …, 2021 - frontiersin.org
The development of more effective, accessible, and easy to administer COVID-19 vaccines
next to the currently marketed mRNA, viral vector, and whole inactivated virus vaccines is …
next to the currently marketed mRNA, viral vector, and whole inactivated virus vaccines is …
mRNA vaccination drives differential mucosal neutralizing antibody profiles in naive and SARS-CoV-2 previously-infected individuals
S Longet, A Hargreaves, S Healy, R Brown… - Frontiers in …, 2022 - frontiersin.org
Two doses of BNT162b2 mRNA vaccine induces a strong systemic SARS-CoV-2 specific
humoral response. However, SARS-CoV-2 airborne transmission makes mucosal immune …
humoral response. However, SARS-CoV-2 airborne transmission makes mucosal immune …
Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19
Introduction As underlined by the late 2019 outbreak of severe acute respiratory syndrome-
coronavirus-2 (SARS-CoV-2), vaccination remains the cornerstone of global health-care …
coronavirus-2 (SARS-CoV-2), vaccination remains the cornerstone of global health-care …
Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection
J Fröberg, DA Diavatopoulos - Current opinion in infectious …, 2021 - journals.lww.com
Although most clinical studies focus on antibodies and cellular immunity in peripheral blood,
mucosal immune responses in the respiratory tract play a key role in the early restriction of …
mucosal immune responses in the respiratory tract play a key role in the early restriction of …
Innate and adaptive immune responses in the upper respiratory tract and the infectivity of SARS-CoV-2
R Ramasamy - Viruses, 2022 - mdpi.com
Increasing evidence shows the nasal epithelium to be the initial site of SARS-CoV-2
infection, and that early and effective immune responses in the upper respiratory tract (URT) …
infection, and that early and effective immune responses in the upper respiratory tract (URT) …
COVID-19: Mechanisms of vaccination and immunity
DE Speiser, MF Bachmann - Vaccines, 2020 - mdpi.com
Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines
that induce large quantities of high affinity virus-neutralizing antibodies may optimally …
that induce large quantities of high affinity virus-neutralizing antibodies may optimally …